GlassScriptPhysician profile
Matthew Lewis
NPI 1205987831
$9,041.27
in general payments reported to CMS, 2019-2025
30 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $319 · 2021: $786 · 2022: $3,804 · 2023: $1,209 · 2024: $1,237 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,532.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $2,300.00 | 2022 | |
| Alcon Vision LLC | $1,233.55 | 2020-2025 | Hydrus Microstent, Argos, Clareon |
| Bausch & Lomb Americas INC. | $935.40 | 2022-2025 | Xiidra, Miebo, Akreos Ao Iol |
| Rxsight INC | $586.57 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Abbvie INC. | $467.44 | 2022-2025 | |
| Allergan, INC. | $460.90 | 2019-2022 | |
| Glaukos Corporation | $408.53 | 2020-2024 | Idose |
| Apellis Pharmaceuticals, INC. | $337.70 | 2023-2025 | Syfovre |
| Sun Pharmaceutical Industries INC. | $301.83 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $286.15 | 2022-2025 | Eylea Hd |
| Johnson & Johnson Surgical Vision, INC. | $250.34 | 2021-2025 | Tecnis Iol, Catalys System, Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $243.25 | 2019-2021 | |
| Ivantis, INC | $240.10 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $161.37 | 2021-2024 | Acthar |
| Biogen, INC. | $114.34 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $112.33 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $103.74 | 2020-2022 | |
| Genentech USA, INC. | $97.23 | 2022-2025 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $81.62 | 2019-2021 | |
| Dompe US, INC. | $66.54 | 2025 | Oxervate |
| Thea Pharma INC. | $36.19 | 2023-2025 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $36.14 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $33.49 | 2022-2024 | |
| Sight Sciences, INC. | $32.47 | 2020-2021 | |
| Polarityte, INC. | $23.53 | 2019 | |
| Harrow Eye, LLC | $20.41 | 2023 | Iheezo |
| Rayner Intraocular Lenses Limited | $19.86 | 2024 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Horizon Therapeutics Plc | $19.04 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $17.83 | 2022 | |
| Ocular Therapeutix, INC. | $13.38 | 2024 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.